Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

Bone Marrow Transplantation volume 29, pages S10–S13 (2002)Cite this article

Abstract

Mantle cell lymphoma (MCL) responds poorly to standard chemotherapy regimens used in non-Hodgkin's lymphoma. As a result, a combination of high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is being investigated in patients with MCL. So far, however, there is no evidence for long-term remission – believed, in part, to be due to contamination of the transfusion product with residual cancer cells. Many ex-vivo purging methods have been developed to remove tumour cells, but these are complicated, time-consuming and expensive. This study describes an in vivo purging method using rituximab to produce a tumour-free stem cell product for re-infusion following HDT. The regimen is split into a purging phase and a myeloablative phase, which together consist of four-step high-dose sequential chemotherapy (sHDT) and six infusions of rituximab immunotherapy. The sHDT comprises cyclophosphamide, cytosine arabinoside, melphalan and mitoxantrone plus melphalan. There are two separate stem cell harvests and three reinfusions. In a pilot study 28 patients with untreated MCL received standard chemotherapy followed by sHDT with rituximab in vivo purging. Preliminary results indicate that in PCR analyses of leukaphereses from 20 assessable patients, 100% lymphoma-negative harvests were achieved following in vivo purging. PCR analyses of the bone marrow following the four-step high-dose regimen with purging and transplantation showed that all patients achieved molecular remission. After a median follow-up of 22 months (range 10–42 months), two patients had died while 26 were alive and disease free. This method allows efficient in vivo purging in the context of an effective chemotherapy regimen and may have a role as first-line therapy in MCL patients who respond poorly to standard treatment.

Bone Marrow Transplantation (2002) 29, Suppl. 1, S10–S13. doi:10.1038/sj.bmt.1703296

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361 1392

    CAS  Google Scholar 

  2. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 Histopathology 2000 36: 69 86

    Article  CAS  Google Scholar 

  3. Rimokh R, Berger F, Delsol G et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas Blood 1994 83: 1871 1875

    CAS  PubMed  Google Scholar 

  4. de Boer CJ, Schuuring E, Dreef E et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma Blood 1995 86: 2715 2723

    CAS  PubMed  Google Scholar 

  5. Press O, Grogan T, Fisher R . Evaluation and management of mantle cell lymphoma Adv Leuk Lymph 1996 6: 3

    Google Scholar 

  6. Hiddemann W, Brittinger G, Tiemann M et al. Clinical characteristics and response to chemotherapy of mantle cell lymphomas – results of a European survey Blood 1996 88: 674a

    Google Scholar 

  7. Haas R, Brittinger G, Meusers P et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma Leukemia 1996 10: 1975 1979

    CAS  Google Scholar 

  8. Blay JY, Sebban C, Surbiguet C et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients Bone Marrow Transplant 1998 21: 51 54

    Article  CAS  Google Scholar 

  9. Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 1998 16: 3803 3809

    Article  CAS  Google Scholar 

  10. Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission J Clin Oncol 1998 16: 13 18

    Article  CAS  Google Scholar 

  11. Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease Blood 1997 90: 4212 4221

    CAS  Google Scholar 

  12. Tarella C, Corradini P, Astolfi M et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions Leukemia 1999 13: 1456 1462

    Article  CAS  Google Scholar 

  13. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting Blood 1997 89: 724 731

    CAS  Google Scholar 

  14. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Blood 2000 96: 864 869

    CAS  Google Scholar 

  15. Tarella C, Gavarotti P, Caracciolo D et al. Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas Ann Oncol 1995 6 (Suppl. 4): 3 8

    Article  Google Scholar 

  16. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol 1999 5 (Suppl. 14): 115 122

    Google Scholar 

  17. Goldberg SL, Pecora AL, Jennis AA et al. Rituximab permits in-vivo purging and collection of tumor-free stem cells prior to autologous transplantation for B-cell non-Hodgkin's lymphoma Blood 1999 94 (Suppl. 1): 141a

    Google Scholar 

  18. Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts) Blood 1999 94 (Suppl. 1): 141a

    Google Scholar 

  19. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma Br J Haematol 2000 109: 729 735

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto Nazionale Tumori, Milan, Italy

    AM Gianni, S Cortelazzo, M Magni & M Martelli

Authors
  1. AM Gianni
    View author publications

    Search author on:PubMed Google Scholar

  2. S Cortelazzo
    View author publications

    Search author on:PubMed Google Scholar

  3. M Magni
    View author publications

    Search author on:PubMed Google Scholar

  4. M Martelli
    View author publications

    Search author on:PubMed Google Scholar

Consortia

for the Michelangelo Cooperative

Additional information

Additional Study Investigators: C Tarella, Torino; K Patti, Palermo; E Pogliani, Monza; P Corradini, Milano; G Saglio, Torino; F Benedetti, Verona.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gianni, A., Cortelazzo, S., Magni, M. et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 29 (Suppl 1), S10–S13 (2002). https://doi.org/10.1038/sj.bmt.1703296

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703296

Keywords

This article is cited by

Search

Advanced search

Quick links